Login to Your Account

With Good Phase II Fibrocaps Data in Hand . . .

ProFibrix CEO Speed Dates At #JPM12 for New Investors

By Nuala Moran
BioWorld International Correspondent

Wednesday, January 11, 2012
LONDON – ProFibrix NV announced positive U.S. Phase II data for its Fibrocaps tissue sealant to add to positive results from the European Phase II published in November 2011, and is talking to investors at the J.P. Morgan Healthcare conference in San Francisco this week, looking to raise €20 million to €25 million (US$25.4 million to $31.8 million) for a pivotal Phase III trial.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription